Bruker Corporation Q3 2026 Earnings Webcast - BRUKER CORP

Financial Performance:

• Q3 2026 reported revenue reached $874 million (+1.6% YoY), with organic growth of 0.7%; year-to-date revenue was $2.54 billion (+3.1% YoY).
• Non-GAAP gross margin expanded 120 basis points to 51.3%, while non-GAAP operating margin surged 400 basis points to 16.3%.
• Diluted non-GAAP EPS for Q3 was $0.56 (+24% YoY); GAAP diluted loss per share was $0.81, impacted by a $175 million non-cash goodwill impairment charge related to Bruker Spatial Biology.
• Free cash flow improved by $151 million YoY; debt was reduced by $58 million in the quarter, lowering the net leverage ratio to 2.4x, below the target.
• Acquisitions contributed 1.7% to top-line growth, partially offset by a 0.6% foreign exchange headwind; constant exchange rate revenue grew 2.4%.
• BSI organic instrument revenue declined mid-single digits due to semiconductor metrology push-outs, offset by high-single-digit organic aftermarket growth.

Guidance and Future Outlook:

• Full-year 2026 reported revenue guidance raised to $3.52–$3.56 billion (up 2.5–3.5% YoY), with currency expected to be neutral to positive.
• Non-GAAP EPS guidance for 2026 remains $2.10–$2.15 (up 15–17% YoY), supported by 250–300 bps of margin expansion.
• Q4 2026 outlook projects lower-mid-single-digit organic revenue growth and significant sequential/YoY margin and EPS increases driven by volume, mix, and compounding cost savings.
• Management targets >100 bps of further operating margin expansion and double-digit EPS growth in 2027, though specific 2027 guidance will be provided in February 2027.
• Strong bookings trends in semiconductor metrology (>30% YoY) and China (>20% YoY) are expected to drive revenue conversion primarily in FY27 and FY28.

Business Segments and Product Lines:

• Biosystems: Year-to-date revenue $1.2 billion (low-single-digit CER growth); driven by IR/Raman and mass spectrometry (top work acquisition), offset by NMR softness.
• Microbiology & Infection Diagnostics (BMID): Year-to-date revenue $396 million (low-single-digit growth); robust growth in molecular diagnostics and new product launches like WAVE for antibiotic susceptibility testing.
• Nano Products: Year-to-date revenue $770 million (low-single-digit CER decline); strong semi-metrology and biopharma growth offset by AcaGov and industrial weakness.
• BEST (Deep Tech): Revenue grew 8.3% in CER (net of eliminations); driven by fusion energy (ITER) orders, high-energy physics, and superconductors.
• Strategic Initiatives: Acquired majority stake in Mimetas (humanized organs-on-a-chip) and invested in Atenaeary Technologies (AI-driven chemistry R&D) to enhance drug discovery workflows.
• Product Advances: New workflows launched for TIMS-ultra (single-cell proteomics) and TIMS Omni (glycobiology, RNA analysis), targeting deeper disease biology insights.

Market and Competitive Landscape:

• U.S. AcaGov: Bookings grew double-digits YoY, marking the first sequential growth since the 2025 NIH funding disruption; potential tailwinds from mid-term election results.
• China: BSI organic bookings up >20% YoY across broad end markets, with recovery in AcaGov sectors; revenue growth in EMEA also exceeded 30%.
• Semiconductors: Driven by the AI megatrend (logic, HBM, advanced packaging); order growth >30% YoY with longer conversion timelines.
• Pharma/Biopharma: Mixed but generally positive trends; stronger growth in regulated spaces compared to CapEx-heavy drug discovery front-ends.
• Competition: Positioning as a leader in "deep biology" tools necessary for AI frontier models, distinguishing from traditional affinity or MS-based methods.

Risks and Challenges:

• Goodwill Impairment: A $175 million charge related to Spatial Biology reflects current weakness in U.S. AcaGov market conditions.
• Timing & Conversion: Semiconductor and NMR orders have longer conversion times (6–9 months for instruments, longer for deep tech), delaying revenue recognition from strong booking trends.
• Geopolitical & Currency: Potential headwinds from tariffs, geopolitical tensions, and currency fluctuations (though FX is expected neutral for FY26).
• Customer Site Readiness: Execution risks persist due to potential delays in customer site readiness for installation, adding ~$20 million quarterly uncertainty.
• China Market Volatility: Difficulty in forecasting market trends beyond a few quarters due to the dynamic nature of the Chinese economy.

Management Commentary and Tone:

• Tone: Cautiously optimistic and confident; management emphasizes "de-risking" the fourth quarter and achieving a "meaningful ramp" into 2027.
• Key Narrative: Shift from recovery to acceleration driven by cost discipline ($140M annualized cost-out target on track) and strong bookings in AI and biotech.
• Strategic Focus: Heavy emphasis on "deep biology" solutions, AI integration, and the transition from animal models to humanized physiologic models (Mimetas).
• Confidence: Express high confidence in the durability of the China and U.S. AcaGov order recovery, viewing current quarters as a foundation for 2027 growth.

Analyst Questions and Answers:

• Margin Drivers: Management attributed Q3 margin expansion to favorable mix (NMR, optical microscopy) and early recognition of cost savings; expects Q4 margin to step up further to high teens.
• AI Contribution: Confirmed AI drives semi-metrology (>30% growth) and bio-discovery (ChemSpeed, SciWise software); significant ramp expected in 2027 as deeper biology tools mature.
• BSI Conversion: Explained that Q3 revenue missed bookings inflection due to semiconductor push-outs and NMR softness; expects organic BSI growth to accelerate in Q4 and 2027.
• 2027 Outlook: Reiterated commitment to double-digit EPS growth and >100 bps margin expansion; cautioned against specific long-term precision due to dynamic end-market timing.
• Tax Rate: Guidance set at ~27.5% for 2026, with a target to reduce 50 bps YoY in 2027-2028 via tax planning initiatives.
• M&A Strategy: Confirmed capacity for future M&A now that leverage targets are met; focus remains on accretive, technology-enhancing bolt-ons.

Other Key Points:

• BSI Book-to-Bill ratio has exceeded 1.0 for five consecutive quarters, signaling sustained order momentum.
• The $20 million semiconductor revenue push-out from Q3 is expected to partially benefit Q4 and early 2027.
• New product launches in BMID, specifically WAVE for antibiotic testing, aim to save lives by shortening ICU times and are seeking FDA clearance by end of year/Q1.
• Management noted that while U.S. AcaGov funding remains non-linear, "pent-up demand" for advanced tools is driving order placement.
• The company expects to achieve a "more typical" growth profile of 200–300 bps above market rates in 2028/2029.